Earth Science Tech

Earth Science Tech

Earth Science Tech, Inc. is a Florida-domiciled, publicly traded entity on the OTC markets that has undergone several corporate transformations. The company positions itself within the health sciences sector, developing and marketing nutritional supplements, cannabinoid-based formulations, and diagnostic technologies. Its revenue model is structured around product commercialization, not investment management, distinguishing it from a traditional family office. The firm has historically pursued market opportunities in the CBD space, including the development of hyaluronic acid and hemp oil formulations aimed at chronic conditions. The company's strategy has historically split across multiple verticals. It has marketed a portfolio of vitamins, minerals, and cannabinoid-based consumer goods through e-commerce channels. A second leg focused on medical devices, specifically a patented sexually transmitted infection testing kit, though that subsidiary's operational status remains unclear. The firm has also indicated ambitions in the pharmaceutical research sector, targeting clinical trial pathways for complex formulations. Due to the company's micro-cap status and limited institutional following, detailed disclosure on current product sales and active R&D pipelines is minimal, relying on periodic OTC Markets filings and press releases. The corporate structure reflects a small, publicly listed operating company rather than a private investment vehicle. Its board and management reports directly to public shareholders, and the company has historically utilized equity financing and convertible instruments to fund operations. The most recent publicly available material suggests an entity managing regulatory compliance challenges and seeking to stabilize its core nutraceutical product line while navigating the capital constraints typical of a micro-cap issuer. Structurally, Earth Science Tech differs from a family office in that it aggregates retail investor capital into operational product lines, not managed portfolios. Governance sits with a board of directors accountable to public markets. The key differentiator — and vulnerability — is its dual identity as both a consumer brand and an aspirational biotech startup, operating with a lean public-company infrastructure that has historically relied on venture-stage financing tactics within a public market context.